Objective To understand how resistance and whether its compensatory hyperinsulinemia will influence the ovulatory function and sex hormone level,especially in the testosterone level and blood lipid level and to observe the effects of metformin on the polycystic ovary syndrome with pseudoacanthosis nigricans and the insulin resistance.Methods The method of the research is to carry out a three-month tretment for 30 patients who were suffering from the polycystic ovary syndrome with the pseudoacanthosis nigricans and the insulin resistance.During the treatment much attention was drawn to the following aspects of the patients.Such as the body mass index,the waist hip ratio,the fasting blood glucose,the fasting insulin,two hours after postcibal blood glucose and postcibal insulin,the insulin sensitive index,the change of blood lipid and sex hormone level,and the skin lesion change.Results After the treatment,all the indexes fell except that the insulin sensitive index rose.There was significancely difference(P

Continuous flow left ventricular assist devices (CF-LVAD) have become one of the long-term treatment options for patients with end-stage heart failure. In such patients, ventricular arrhythmia (VA) is a common complication after implantation. Severe VA after CF-LVAD implantation can cause adverse events such as impaired right ventricular filling and hemodynamic deterioration, which in turn affects the patient's prognosis. By reviewing the relevant research progress of VA after CF-LVAD implantation, this article provides an overview of the epidemiology, perioperative management, and therapeutic options of postimplantation VA, aiming to summarize the pathogenesis, clinical manifestations, and prognostic outcomes of postimplantation VA, and to provide ideas for a more comprehensive and in-depth study.

Programmed cell death ligand 1 (PD-L1)/programmed cell death protein 1 (PD-1) cascade is an effective therapeutic target for immune checkpoint blockade (ICB) therapy. Targeting PD-L1/PD-1 axis by small-molecule drug is an attractive approach to enhance antitumor immunity. Using flow cytometry-based assay, we identify tubeimoside-1 (TBM-1) as a promising antitumor immune modulator that negatively regulates PD-L1 level. TBM-1 disrupts PD-1/PD-L1 interaction and enhances the cytotoxicity of T cells toward cancer cells through decreasing the abundance of PD-L1. Furthermore, TBM-1 exerts its antitumor effect in mice bearing Lewis lung carcinoma (LLC) and B16 melanoma tumor xenograft